Ammann, N.L.; Schwietzer, Y.F.; Mess, C.; Stadler, J.-C.; Geidel, G.; Kött, J.; Pantel, K.; Schneider, S.W.; Utikal, J.; Bauer, A.T.;
et al. Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. Cancers 2022, 14, 5676.
https://doi.org/10.3390/cancers14225676
AMA Style
Ammann NL, Schwietzer YF, Mess C, Stadler J-C, Geidel G, Kött J, Pantel K, Schneider SW, Utikal J, Bauer AT,
et al. Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. Cancers. 2022; 14(22):5676.
https://doi.org/10.3390/cancers14225676
Chicago/Turabian Style
Ammann, Nadine L., Yasmin F. Schwietzer, Christian Mess, Julia-Christina Stadler, Glenn Geidel, Julian Kött, Klaus Pantel, Stefan W. Schneider, Jochen Utikal, Alexander T. Bauer,
and et al. 2022. "Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma" Cancers 14, no. 22: 5676.
https://doi.org/10.3390/cancers14225676
APA Style
Ammann, N. L., Schwietzer, Y. F., Mess, C., Stadler, J. -C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J., Bauer, A. T., & Gebhardt, C.
(2022). Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. Cancers, 14(22), 5676.
https://doi.org/10.3390/cancers14225676